Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you offer bevacizumab to a patient with colorectal cancer and a history of inflammatory bowel disease?
Related Questions
How long would you continue trastuzumab for a patient with metastatic HER2+ esophageal adenocarcinoma whose tumor has achieved CR with FOLFOX + trastuzumab and has been disease-free for nearly 3 years?
Would you include HER2 directed therapy in the treatment of HER2+ small bowel adenocarcinoma?
Would you treat an unresectable MSI-H colon cancer patient with persistent hepatitis C with immunotherapy?
What are your top takeaways from ASCO GI 2024?
What do you recommend for patients with stage 3 MSI-H colorectal cancer who are ineligible for oxaliplatin-based adjuvant therapy?
How would you manage a patient with metastatic HCC on atezolizumab/bevacizumab who requires holding bevacizumab due to persistent proteinuria >2g?
How would you approach a clinical stage 3 sigmoid colon cancer, dMMR/MSI-H with comorbidities and increased risk of surgical complications?
Would you recommend off-label use of chemoimmunotherapy for metastatic anal squamous cell cancer?
Would you recommend additional post-operative chemoradiation for a T2N1 proximal rectal cancer having received adjuvant capecitabine/oxaliplatin?
Would you typically offer adjuvant FOLFOX or XELOX to a pT4b pN0 colon cancer?
